Mumps Therapeutics - Pipeline Analysis, Clinical Trials & Results

Mumps is a transmissible disease caused by the mumps virus and is characterized by swelling of glands in neck and face. Some of the symptoms of this disease are headache, fever, tiredness, loss of appetite, and muscle ache.

Request to Get Sample Pages at:  https://www.pharmaproff.com/request-sample/1067

The disease can be transferred from an infected person through coughing; sneezing; and sharing items, such as razors and utensils. According to the Centers for Disease Control and Prevention, a study from January 2017 to July 2017 covering 46 states of the U.S., estimated that around 3,886 people have mumps infection.

Make Enquiry Before Buying the Report:https://www.pharmaproff.com/enquiry/1067 

The complications associated with mumps include encephalitis, orchitis, mastitis, meningitis, and deafness. Daiichi Sankyo Co. Ltd. is in the process of developing VN-0102 as a measles-mumps-rubella vaccine for the treatment of mumps. Cadila Healthcare Limited is also involved in the development of drug candidates for the treatment of this disease.

Access Detailed Report Summary: https://www.pharmaproff.com/report/mumps-therapeutics-pipeline-analysis

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Middle East Respiratory Syndrome (MERS) Therapeutics Pipeline Analysis

Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a coronavirus (MERS-CoV). Coronaviruses are a type of viruses that affect the respiratory tract of mammals, including humans. Human coronaviruses usually cause mild to moderate cold-like illnesses. However, MERS-CoV is different from any other coronavirus previously found in people.

Request to Get Sample Pages at: https://www.pharmaproff.com/request-sample/1066

The infected patients may have mild symptoms or no symptoms at all, but most people infected with MERS-CoV develop severe respiratory illness, fever, cough, and shortness of breath. Some patients have reported to have gastrointestinal symptoms like diarrhea and nausea/vomiting; and kidney failure. MERS-CoV is known to spread from an infected person to others through respiratory secretions like coughing. However, the precise way in which this virus spreads has not been well understood yet. Some of the companies having drugs in the MERS syndrome pipeline includes Atriva Therapeutics GmbH and Inovio Pharmaceuticals Inc. are known to be involved in MERS pipeline.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Make Enquiry Before Buying the Report: https://www.pharmaproff.com/enquiry/1066

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Klebsiella Infections Therapeutics Pipeline Analysis, Clinical Trials & Results

Klebsiella infections include different types of infections like bloodstream infections; pneumonia; wound or surgical site infections; and meningitis, caused by the Klebsiella bacteria. The symptoms associated with these infections are high fevers, chills, cough, and shortness of breath.

Request to Get Sample Pages at:   https://www.pharmaproff.com/request-sample/1065

Hospitalized patients undergoing treatment for other conditions may be susceptible to these infections. In healthcare settings, patients who require long courses of antibiotics, or are treated with devices like ventilators or intravenous catheters are at a high risk of developing these infections.

Although these infections are often treated with antibiotics, but some Klebsiella bacteria may be resistant to certain types of antibiotics. Arsanis Inc. is in the process of developing ASN300 as a monoclonal antibody for the treatment of Klebsiella infections.

Make Enquiry Before Buying the Report: https://www.pharmaproff.com/enquiry/1065

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Impetigo Therapeutics: Drug Development Pipeline Analysis

Impetigo is a common bacterial infection caused by different kinds of bacteria, including streptococcus and staphylococcus. It is a contagious disease and begins with appearance of red sores on any part of the body, which eventually changes to blisters on the body.

Request to Get Sample Pages at:  

                                                   https://www.pharmaproff.com/request-sample/1064

Impetigo is more common in warm and humid weather, is known to easily transmit in crowded settings like schools and day care. Impetigo can be treated by topical antibiotics, oral antibiotics and some home remedies. It is mostly found in children, especially boys, but may also affect adults if they have a weak immune system. Foamix Pharmaceuticals is in the process of developing FMX102 for the treatment of impetigo. Destiny Pharma plc is also involved in the pipeline for impetigo therapeutics.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Make Enquiry Before Buying the Report:

                                                                    https://www.pharmaproff.com/enquiry/1064

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Ischemic Stroke Therapeutics - Pipeline Analysis, Clinical Trials & Results, Patents

Ischemic stroke develops due to an obstruction within a blood vessel which supply blood to the brain. The underlying condition for this type of obstruction is atherosclerosis, which is characterized by fatty deposition or plaque build-up in the blood vessels.

Request to Get Sample Pages at:  

                                                  https://www.pharmaproff.com/request-sample/1103

Ischemic stroke is categorized into two types which includes embolic stroke and thrombotic stroke. According to the American Stroke Association, strokes are the second leading cause of death in the world. Several risk factors associated with the ischemic stroke are high blood pressure, diabetes, atrial fibrillation, high cholesterol level, obesity, inactivity, unhealthy diet, smoking, and aging.

Make Enquiry Before Buying the Report:

                                                                https://www.pharmaproff.com/request-sample/1103

Lumosa Therapeutics Co. Ltd. is in the process of developing LT – 3001 as a small molecule with thrombolytic and anti-oxidative functions for the treatment of acute ischemic stroke. Some of the other companies having pipeline drugs for ischemic stroke includes International Stem Cell Corporation, and NoNO Inc.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Hyperalgesia Therapeutics - Pipeline Analysis, Clinical Trials & Results

Hyperalgesia is a medical condition in which a person develops an increased sensitivity towards pain. There are several nerve pathways in the body where signals can start miscommunication with each other, resulting in hyperalgesia.

Request to Get Free Sample Pages at:  https://www.pharmaproff.com/request-sample/1100

Hyperalgesia can be categorized into several types which includes primary, secondary and opioid-induced hyperalgesia. The main symptom associated with the disease is increasing extreme reaction to painful stimuli without any new injury.

Make Enquiry Before Buying the Report: https://www.pharmaproff.com/enquiry/1100

The disease can be treated with non-opioid medications, methadone, buprenorphine, and ketamine. Company like Rottapharm Biotech Srl is in the process of developing CRB0089 as an anti-TrkA therapeutic monoclonal antibody for the treatment of hyperalgesia.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Pharmacological Therapies for Asperger Syndrome

Asperger syndrome is an autism spectrum disorder characterized by impaired communication skills and repetitive thoughts or behavior. Symptoms associated with the Asperger syndrome are lack of speech recognition skills, dislike for routine changes, avoidance of eye contacts, unusual facial expressions, and delayed motor development.

Request to Get Free Sample Pages at:  

                                                     https://www.pharmaproff.com/request-sample/1092

The treatment of the disease involves social training skills, medications, and cognitive behavioral therapy. However, the actual cause of the disease is still unknown. AgeneBio Inc. is in the process of developing GABAA α5 positive allosteric modulator for the treatment of Asperger syndrome. GW Pharmaceuticals plc is in the process of developing GWP42006 as a cannabinoid receptor modulator for the treatment of this disease.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/asperger-syndrome-therapeutics-pipeline-analysis

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Make Enquiry Before Buying the Report:

                                                               https://www.pharmaproff.com/enquiry/1092

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Von Hippel-Lindau Syndrome Therapeutics - Pipeline Analysis 2020, Clinical Trials & Results

Von Hippel-Lindau syndrome is a genetic disorder characterized by formation of cysts and tumors in different parts of the body. The symptoms associated with the disease depends upon the location of tumor.

However, gait disturbance, dizziness, weakness of the limbs, deafness, high blood pressure, and vision problems are some common symptoms observed in the patients. The available treatment options for the disease are surgical removal of the tumor, high dose irradiation, and chemotherapies.

Request to Get Free Sample Pages at:  

                                                 https://www.pharmaproff.com/request-sample/1091

Von Hippel-Lindau syndrome is mostly found to be associated with pheochromocytoma. The National Eye Institute (NEI), based in the U.S., is in the process of developing a combination therapy of ranibizumab and E10030 for the treatment of von Hippel-Lindau syndrome.

Make Enquiry Before Buying the Report:

                                                                   https://www.pharmaproff.com/enquiry/1091

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Focal Segmental Glomerulosclerosis (FSGS) Therapeutics - Pipeline Analysis 2020, Clinical Trials & Results

Focal segmental glomerulosclerosis (FSGS) is a glomerular disease, which is characterized by scarring or sclerosis in the kidney. Scarring damages the limited number of glomeruli in the initial stages. It is more common in males than in females, and is very common in African American population.

FSGS can be caused by many diseases like diabetes, sickle cell disease, and HIV infection. It is categorized into two types; primary and secondary FSGS, and can be treated using corticosteroids, ACE inhibitors, immunosuppressive drugs, diuretics, and diet modification.

Request to Get Free Sample Pages at:  

                                          https://www.pharmaproff.com/request-sample/1090

Retrophin Inc. is in the process of developing Sparsentan, with dual mechanism of action that combines angiotensin receptor blockade with endothelin receptor blockade for the treatment of FSGS. Some other companies in FSGS pipeline are Variant Pharmaceuticals Inc. and ChemoCentryx Inc.

Make Enquiry Before Buying the Report:

                                                          https://www.pharmaproff.com/enquiry/1090

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Polymyalgia Rheumatica Therapeutics - Pipeline Analysis, Clinical Trials & Results

Polymyalgia rheumatica is an inflammatory disorder which causes stiffness and aching, and usually affects adults over the age of 50 years. This disease affects women somewhat more than men. The cause of polymyalgia rheumatica is unknown.

Access Detailed Report Summary:

https://www.pharmaproff.com/report/polymyalgia-rheumatica-therapeutics-pipeline-analysis

Polymyalgia rheumatica is related to another inflammatory disorder, giant cell arteritis, which can cause vision difficulties, scalp tenderness, jaw pain, and headaches. Pain in shoulders, neck, upper arms, buttocks, hips and thighs; stiffness in the affected areas; limited range of motion in affected areas; and stiffness in wrists, elbows and knees are some of the common symptoms of polymyalgia rheumatica.

Request to Get Free Sample Pages at:  

                                                 https://www.pharmaproff.com/request-sample/1087

Involvement of the upper arms, with trouble raising them above the shoulders is common in the patients with this disease. Corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs) are common medications for the treatment of polymyalgia rheumatica. GlaxoSmithKline plc is in the process of developing sirukumab as an interleukin 6 (IL6) human monoclonal antibody for the treatment of polymyalgia rheumatica. Other than this Chugai Pharmaceutical Co. Ltd., and Eli Lilly and Company are also involved in polymyalgia rheumatica pipeline.

Make Enquiry Before Buying the Report:

                                                               https://www.pharmaproff.com/enquiry/1087

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More

Sezary Syndrome Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results

Sézary syndrome, a type of cutaneous T-cell lymphoma, affects Sézary cells present in the skin, lymph nodes and blood. It accounts approximately 3 to 5 percent of cases of cutaneous T-cell lymphoma. Sézary syndrome is more prevalent in males compared to females.

It is characterized by red, severely itchy rash that covers large areas of the body. The common symptoms of Sézary syndrome includes alopecia, lymphadenopathy, palmoplantar keratoderma, ectropion and abnormalities of the fingernails and toenails.

Request to Get the Sample Pages at:  

The standard treatments for Sézary syndrome are combination of phototherapy and chemotherapy, and medications including vorinostat and romidepsin. Takeda Pharmaceutical Company Limited is in the process of developing brentuximab vedotin for the treatment of Sézary syndrome.

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More..

Read More

Bone Metastases Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents

Bone metastases is a common form of cancer of the skeleton that inhabits in bone marrow and stimulates the local bone activity. In this condition, the normal bone homeostasis disrupts which leads to the development of the tumour. Some of the major symptoms observed in patients with bone metastases are bone pain, spinal cord compression, and high blood calcium levels.

Bone metastases can be diagnosed by various types of imaging tests such as X-Ray, bone scan, positron emission tomography (PET), magnetic resonance imaging (MRI), and computed tomography (CT) scan, blood tests, urine tests, and bone biopsy. ChemoCentryx, Inc. is in the process of developing CCX354 as a CCR1 receptor antagonist for the treatment of bone metastases. Moreover, Amgen Inc. is developing denosumab as a RANKL ligand inhibitor for the treatment of this medical condition. Pfizer Inc., and Eli Lilly and Company are also key players having drugs for bone metastases in their pipeline.

Request to Get the Sample Pages at: 

The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.

Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.

Read More…

Read More